AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of SEK 2.77 trillion. The enterprise value is 3.06 trillion.
Market Cap | 2.77T |
Enterprise Value | 3.06T |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
Earnings Date | Nov 12, 2024 |
Ex-Dividend Date | Aug 8, 2024 |
Share Statistics
Shares Outstanding | n/a |
Shares Change (YoY) | +0.16% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 1.54B |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 5.31 |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.65, with an EV/FCF ratio of 30.63.
EV / Earnings | 44.82 |
EV / Sales | 5.84 |
EV / EBITDA | 16.65 |
EV / EBIT | 23.28 |
EV / FCF | 30.63 |
Financial Position
The company has a current ratio of 0.89, with a Debt / Equity ratio of 84.97.
Current Ratio | 0.89 |
Quick Ratio | 0.69 |
Debt / Equity | 84.97 |
Debt / EBITDA | 1.95 |
Debt / FCF | 3.57 |
Interest Coverage | 9.65 |
Financial Efficiency
Return on equity (ROE) is 16.74% and return on invested capital (ROIC) is 10.91%.
Return on Equity (ROE) | 16.74% |
Return on Assets (ROA) | 7.68% |
Return on Capital (ROIC) | 10.91% |
Revenue Per Employee | 5.79M |
Profits Per Employee | 759,256 |
Employee Count | 89,900 |
Asset Turnover | 0.49 |
Inventory Turnover | 1.59 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +19.81% in the last 52 weeks. The beta is 0.15, so AstraZeneca's price volatility has been lower than the market average.
Beta (5Y) | 0.15 |
52-Week Price Change | +19.81% |
50-Day Moving Average | 1,695.89 |
200-Day Moving Average | 1,512.84 |
Relative Strength Index (RSI) | 64.03 |
Average Volume (20 Days) | 197,013 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of SEK 520.76 billion and earned 68.26 billion in profits. Earnings per share was 43.66.
Revenue | 520.76B |
Gross Profit | 430.24B |
Operating Income | 130.86B |
Pretax Income | 82.10B |
Net Income | 68.26B |
EBITDA | 179.90B |
EBIT | 130.86B |
Earnings Per Share (EPS) | 43.66 |
Balance Sheet
The company has 75.00 billion in cash and 356.60 billion in debt, giving a net cash position of -281.60 billion.
Cash & Cash Equivalents | 75.00B |
Total Debt | 356.60B |
Net Cash | -281.60B |
Net Cash Per Share | n/a |
Equity (Book Value) | 419.70B |
Book Value Per Share | 270.18 |
Working Capital | -33.63B |
Cash Flow
In the last 12 months, operating cash flow was 117.28 billion and capital expenditures -17.41 billion, giving a free cash flow of 99.86 billion.
Operating Cash Flow | 117.28B |
Capital Expenditures | -17.41B |
Free Cash Flow | 99.86B |
FCF Per Share | n/a |
Margins
Gross margin is 82.62%, with operating and profit margins of 25.13% and 13.11%.
Gross Margin | 82.62% |
Operating Margin | 25.13% |
Pretax Margin | 15.77% |
Profit Margin | 13.11% |
EBITDA Margin | 34.55% |
EBIT Margin | 25.13% |
FCF Margin | 19.18% |
Dividends & Yields
AstraZeneca does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | 3.66% |
Years of Dividend Growth | 2 |
Payout Ratio | 69.29% |
Buyback Yield | -0.16% |
Shareholder Yield | -0.16% |
Earnings Yield | 2.45% |
FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |